Related Experiment Video
Updated: Jun 30, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung
Hao Bai1, Yan Zhou1, Wanting Liu1
1Department of Pulmonary and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
Introduction:
The genetic heterogeneity of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations may affect clinical responses and outcomes to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This study aims to investigate the genomic factors that influence the efficacy and clinical outcomes of first-line, second-line and third-line treatments in NSCLC and explore the heterogeneity of resistance mechanisms.
Materials And Methods:
This real-world study comprised 65 patients with EGFR mutant NSCLC. Molecular alterations were detected using a customized DNA panel before and after administering targeted therapy. The efficacy and prognosis of each treatment line were evaluated.
Results:
In first-generation EGFR-TKIs treatment, gefitinib showed favorable efficacy compared to icotinib and erlotinib, particularly in patients with EGFR L858R mutations. The resistance mechanisms to first-generation EGFR-TKIs varied among different EGFR mutation cohorts and different first-generation EGFR-TKIs. In second-line EGFR-TKIs treatment, EPH receptor A3 (EPHA3), IKAROS family zinc finger 1 (IKZF1), p21 (RAC1) activated kinase 5 (PAK5), DNA polymerase epsilon, catalytic subunit (POLE), RAD21 cohesin complex component (RAD21) and RNA binding motif protein 10 (RBM10) mutations were markedly associated with poorer progression-free survival (PFS). Notably, EPHA3, IKZF1 and RBM10 were identified as independent predictors of PFS. The mechanisms of osimertinib resistance exhibited heterogeneity, with a higher proportion of non-EGFR-dependent resistant mutations. In third-line treatments, the combination of osimertinib and anlotinib demonstrated superior efficacy compared to other regimens. Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) mutation was an independent risk indicator of shorter OS following third-line treatments.
Conclusions:
Comprehending the tumor evolution in NSCLC is advantageous for assessing the efficacy and prognosis at each stage of treatment, providing valuable insights to guide personalized treatment decisions for patients.
Insights
This study reveals genetic factors influencing non-small cell lung cancer (NSCLC) treatment outcomes. Understanding tumor evolution guides personalized therapy for EGFR-mutant NSCLC patients.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Genetic heterogeneity in EGFR-mutant non-small cell lung cancer (NSCLC) impacts treatment response to EGFR tyrosine kinase inhibitors (EGFR-TKIs).
- Understanding resistance mechanisms is crucial for optimizing sequential therapies.
Purpose of the Study:
- To investigate genomic factors influencing efficacy and outcomes across first-, second-, and third-line EGFR-TKI treatments in NSCLC.
- To explore the heterogeneity of resistance mechanisms in EGFR-mutant NSCLC.
Main Methods:
- A real-world study involving 65 patients with EGFR-mutant NSCLC.
- Molecular alterations were analyzed using a DNA panel before and after targeted therapy.
- Efficacy and prognosis were evaluated for each treatment line.
Main Results:
- Gefitinib showed superior efficacy in first-generation EGFR-TKI treatment for EGFR L858R mutations.
- Specific mutations (EPHA3, IKZF1, RBM10) were associated with poorer progression-free survival in second-line treatment.
- Osimertinib combined with anlotinib demonstrated superior efficacy in third-line treatment, with GRIN2A mutations predicting shorter overall survival.
Conclusions:
- Tumor evolution in NSCLC is critical for assessing treatment efficacy and prognosis at each stage.
- Insights into genomic alterations and resistance mechanisms can guide personalized treatment strategies for NSCLC patients.
